Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

A Phase II Trial of Mitomycin in Patients with Epithelial Ovarian Carcinoma Resistant to Cisplatin or Carboplatin

Hoskins, P. J., B.A., FRCPC; McMurtrie, E., M.D., FRCPC; Swenerton, K. D., M.D., FRCPC

American Journal of Clinical Oncology: October 1990 - Volume 13 - Issue 5 - p 416–419
Article: PDF Only
Buy

Intravenous bolus mitomycin was given at a dose of 10–12 mg/m2 to patients with epithelial ovarian cancer resistant to cisplatin or carboplatin. There were three (12%) partial responses and no complete responses in the 25 patients so treated.

A. Maxwell Evans Clinic of the Cancer Control Agency of British Columbia, Vancouver, Canada V5Z 4E6

© Lippincott-Raven Publishers.